David M Kent1, Robin Ruthazer2, Carole Decker2, Philip G Jones2, Jeffrey L Saver2, Erich Bluhmki2, John A Spertus2. 1. From the Predictive Analytics and Comparative Effectiveness Center (D.M.K., R.R.), Institute for Clinical Research and Health Policy Studies, Tufts Medical Center/Tufts University School of Medicine, Boston, MA; Saint Luke's Mid America Heart Institute (C.D., P.G.J., J.A.S.), Kansas City, MO; University of Missouri-Kansas City (C.D., P.G.J., J.A.S.); Stroke Center and Department of Neurology (J.L.S.), University of California, Los Angeles; and Boehringer Ingelheim (E.B.), Germany. dkent1@tuftsmedicalcenter.org. 2. From the Predictive Analytics and Comparative Effectiveness Center (D.M.K., R.R.), Institute for Clinical Research and Health Policy Studies, Tufts Medical Center/Tufts University School of Medicine, Boston, MA; Saint Luke's Mid America Heart Institute (C.D., P.G.J., J.A.S.), Kansas City, MO; University of Missouri-Kansas City (C.D., P.G.J., J.A.S.); Stroke Center and Department of Neurology (J.L.S.), University of California, Los Angeles; and Boehringer Ingelheim (E.B.), Germany.
Abstract
OBJECTIVES: The Stroke-Thrombolytic Predictive Instrument (Stroke-TPI) predicts the probability of good and bad outcomes with and without recombinant tissue plasminogen activator (rtPA). We sought to rebuild and externally validate a simpler Stroke-TPI to support implementation in routine clinical care. METHODS: Using the original derivation cohort of 1,983 patients from a combined database of randomized clinical trials (NINDS [National Institute of Neurological Disorders and Stroke] 1 and 2; ATLANTIS [Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke] A and B; and ECASS [European Cooperative Acute Stroke Study] II), we simplified the Stroke-TPI by reducing variables and interaction terms and by exploring simpler (3- and 8-item) stroke severity scores. External validation was performed in the ECASS III trial (n = 821). RESULTS: The following 6 variables were most predictive of good outcomes: age, systolic blood pressure, diabetes, stroke severity, symptom onset to treatment time, and rtPA therapy. Treatment effect modifiers included onset to treatment time and systolic blood pressure. For the models predicting a bad outcome (modified Rankin Scale [mRS] score ≥5), significant variables included age, stroke severity, and serum glucose. rtPA therapy did not change the risk of a poor outcome. Compared with models using the full NIH Stroke Scale, models using the 3-item severity score showed similar discrimination and excellent calibration. External validation on ECASS III showed similar performance (C statistics 0.75 [mRS score ≤1] and 0.80 [mRS score ≤2]). CONCLUSION: A simpler model using a 3-item stroke severity score, instead of the 15-item NIH Stroke Scale, has similar prognostic value and may be easier to use in routine care. Future studies are needed to test whether it can improve process and clinical outcomes.
OBJECTIVES: The Stroke-Thrombolytic Predictive Instrument (Stroke-TPI) predicts the probability of good and bad outcomes with and without recombinant tissue plasminogen activator (rtPA). We sought to rebuild and externally validate a simpler Stroke-TPI to support implementation in routine clinical care. METHODS: Using the original derivation cohort of 1,983 patients from a combined database of randomized clinical trials (NINDS [National Institute of Neurological Disorders and Stroke] 1 and 2; ATLANTIS [Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke] A and B; and ECASS [European Cooperative Acute Stroke Study] II), we simplified the Stroke-TPI by reducing variables and interaction terms and by exploring simpler (3- and 8-item) stroke severity scores. External validation was performed in the ECASS III trial (n = 821). RESULTS: The following 6 variables were most predictive of good outcomes: age, systolic blood pressure, diabetes, stroke severity, symptom onset to treatment time, and rtPA therapy. Treatment effect modifiers included onset to treatment time and systolic blood pressure. For the models predicting a bad outcome (modified Rankin Scale [mRS] score ≥5), significant variables included age, stroke severity, and serum glucose. rtPA therapy did not change the risk of a poor outcome. Compared with models using the full NIH Stroke Scale, models using the 3-item severity score showed similar discrimination and excellent calibration. External validation on ECASS III showed similar performance (C statistics 0.75 [mRS score ≤1] and 0.80 [mRS score ≤2]). CONCLUSION: A simpler model using a 3-item stroke severity score, instead of the 15-item NIH Stroke Scale, has similar prognostic value and may be easier to use in routine care. Future studies are needed to test whether it can improve process and clinical outcomes.
Authors: David L Tirschwell; W T Longstreth; Kyra J Becker; Richard E Gammans; LuAnn A Sabounjian; Scott Hamilton; Lewis B Morgenstern Journal: Stroke Date: 2002-12 Impact factor: 7.914
Authors: David van Klaveren; Yvonne Vergouwe; Vasim Farooq; Patrick W Serruys; Ewout W Steyerberg Journal: J Clin Epidemiol Date: 2015-02-27 Impact factor: 6.437
Authors: T Brott; H P Adams; C P Olinger; J R Marler; W G Barsan; J Biller; J Spilker; R Holleran; R Eberle; V Hertzberg Journal: Stroke Date: 1989-07 Impact factor: 7.914
Authors: Oliver C Singer; Florian Dvorak; Richard du Mesnil de Rochemont; Heiner Lanfermann; Matthias Sitzer; Tobias Neumann-Haefelin Journal: Stroke Date: 2005-02-24 Impact factor: 7.914
Authors: W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas Journal: Lancet Date: 1998-10-17 Impact factor: 79.321
Authors: Eivind Berge; William Whiteley; Heinrich Audebert; Gian Marco De Marchis; Ana Catarina Fonseca; Chiara Padiglioni; Natalia Pérez de la Ossa; Daniel Strbian; Georgios Tsivgoulis; Guillaume Turc Journal: Eur Stroke J Date: 2021-02-19
Authors: Thomas Meinel; Christine Lerch; Urs Fischer; Morin Beyeler; Adnan Mujanovic; Christoph Kurmann; Bernhard Siepen; Adrian Scutelnic; Madlaine Müller; Martina Goeldlin; Nebiyat Filate Belachew; Tomas Dobrocky; Jan Gralla; David Seiffge; Simon Jung; Marcel Arnold; Roland Wiest; Raphael Meier; Johannes Kaesmacher Journal: Neurology Date: 2022-07-08 Impact factor: 11.800
Authors: Elizabeth Holliday; Thomas Lillicrap; Timothy Kleinig; Philip M C Choi; Jane Maguire; Andrew Bivard; Lisa F Lincz; Monica Anne Hamilton-Bruce; Sushma R Rao; Marten F Snel; Paul J Trim; Longting Lin; Mark W Parsons; Bradford B Worrall; Simon Koblar; John Attia; Chris Levi Journal: BMJ Open Date: 2020-04-06 Impact factor: 2.692